Table 6 Demographic characteristics and clinical findings according to the cut-off ELABELA levels in predicting CLL
From: Can ELABELA be a novel target in the treatment of chronic lymphocytic leukaemia?
Variables | ELABELA (ng/ml) | p | |
|---|---|---|---|
≤5.34 N = 14 | > 5.34 N = 28 | ||
Age (years) | 63.7 ± 8.3 | 63.9 ± 10.6 | 0.948 |
Gender | |||
Female | 4 (28.6) | 10 (35.7) | 0.908 |
Male | 10 (71.4) | 18 (64.3) | |
Disease duration (months) | 30 (2–72) | 24 (2–84) | 0.398 |
Stage | |||
0 | – | 7 (25.0) | 0.231 |
1 | 6 (42.9) | 10 (35.7) | |
2 | 4 (28.6) | 6 (21.4) | |
3 | 2 (14.3) | 4 (14.3) | |
4 | 2 (14.3) | 1 (3.6) | |
DC | |||
Negative | 8 (57.1) | 26 (92.9) | 0.011* |
Positive | 4 (28.6) | 1 (3.6) | |
Weak positive | 2 (14.3) | 1 (3.6) | |
p53 | |||
Negative | 3 (50.0) | 12 (80.0) | 0.401 |
Positive | 3 (50.0) | 3 (20.0) | |
DEL13q | |||
Negative | 1 (25.0) | 4 (40.0) | 0.999 |
Positive | 3 (75.0) | 6 (60.0) | |
Haemoglobin (g/dL) | 12 ± 2.2 | 12.7 ± 2.2 | 0.327 |
WBCs (×103/μL) | 29.6 (5.8–128.7) | 25.3 (6.4–131) | 0.539 |
Neutrophils (×103/μL) | 5.6 (0.7–8) | 5.5 (0.6–11.5) | 0.831 |
Lymphocytes (× 103/μL) | 24.3 (5–123) | 17.5 (5.2–116.5) | 0.496 |
Platelets (×103/μL) | 200 (81–463) | 200 (24–350) | 0.800 |